🔗 Share this article

As America continues making historic revisions to its vaccination recommendations, a particular individual has surfaced somewhat surprisingly: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by casting doubt on coronavirus vaccinations in the pandemic and has zeroed in on alleged deaths after COVID-19 immunization in her brief position at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Vaccine Program

Health officials planned to announce major revisions to the pediatric vaccination calendar recently, synchronizing the US with the Danish national calendar, it is understood – a significant shift that would put the US out of alignment with much of the international standard with little proof for benefit. The planned update has been postponed until the next year.

Rather than the director of the vaccine center, Dr. Høeg is listed to speak at the meeting. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the center this year.

Consolidating Power at the Agency

Høeg's temporary position may indicate a strengthened alliance between the pharmaceutical and biologics centers as Dr. Høeg and Prasad solidify control at the agency – and it suggests a increased emphasis upon dismantling previously authorized vaccines at the FDA.

The new acting director has repeatedly called for ending specific childhood shot schedules in the US in order to be more like Denmark, a nation with nationalized medicine and a citizenry roughly the size of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on immunizations – traditionally the domain of Prasad, head of the FDA’s vaccine center – rather than medication approval.

Concerns Over Qualifications

Dr. Høeg has no apparent track record in drug development, regulation or management, which has been standard for past heads of the biologics center. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since spring.

“She doesn’t seem to have the necessary background” for leading the CDER, said Jonathan Howard. “She’s never run a randomized controlled trial. She lacks experience in running a sizeable institution. She lacks background in drug approvals.”

Previous directors of CBER would “understand laws and regulations and the underlying principles of drug development”, noted a former acting FDA commissioner. “Clearly, she lacks the kind of background that former directors who led the center have had.”

This division has an enormous workload at the FDA, Woodcock pointed out.

“Everybody just pays attention on the new drug program, but the generic program authorizes thousands of generic drugs. There’s a biologic copycat branch, over-the-counter program and other areas, and all of those must be looked after,” Dr. Woodcock said. “The area you overlook, that is precisely what that I always told people is going to bite you.”

Additionally, a major administrative component to the position, which supervises in excess of 5,000 staff members. “It is a huge administrative position, if you execute it properly,” the former official said.

Response and Disputed Programs

When asked about questions about Dr. Høeg's fitness for the role and whether this selection represents increased cooperation among agency officials on vaccines, a press secretary stated that the “concerns stem from incorrect assumptions”.

“Her experience aligns with the functions of her position,” the representative said, citing the months Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Høeg takes over the commissioner’s recently launched expedited review system, a disputed one-day medication authorization process that apparently concerned her preceding directors. “How are these drugs being selected for this fast-track system? Who takes the choices?” Howard questioned. “There is a lot of confidentiality happening at the regulatory body right now.”

In general, he said, “the FDA appears to be shifting towards more relaxed rules of pharmaceuticals, with the exception of vaccines.”

Documented Track Record on Vaccines

Concerning vaccines, Høeg has a more established, if troubling, track record, some experts have noted. She released a research paper using unverified crowd-sourced reports to assess the incidence of myocarditis following Covid vaccination. She advised the state of Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccines are more dangerous than they are.

Part of her “desired changes” for the new federal leadership included revising rules for novel immunizations and ending “unnecessary” immunizations, she remarked after the election on a audio program. At the agency, Dr. Høeg has reportedly proposed preventing adolescent males from receiving Covid vaccinations.

“She is an thorough dogmatist who begins with her beliefs and reverse-engineers to fit the data in a highly deceptive, dishonest manner,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Høeg joined other contrarians, {like|